NL
DE
Our mission
We aim to unravel the underlying mechanisms of tumor-immune attack and resistance in a wide variety of cancer types and to contribute to improved clinical outcomes of cancer patients treated with immunotherapy.
Goals
- To unravel the underlying mechanisms of the tumor immune attack and resistance to understand the tumor micro-environment at a (sub)cellular level and to adjust the function of immune cells to improve tumor killing and circumvent tumor-induced resistance.
- To improve the use of currently available immunotherapies by developing biomarkers to select patients to improve efficacy and avoid toxicity and by investigating different schemes (lower dose/shorter duration) to reduce toxicity and costs.
- To develop new immunotherapeutic strategies for clinical application by initiating preclinical in vitro and animal experiments to develop new immunotherapeutic strategies and by starting phase I / II clinical trials at a new multidisciplinary phase I unit (CANTO).
